Cargando…

High density lipoprotein mediates anti-inflammatory transcriptional reprogramming of macrophages via the transcriptional repressor ATF3

High Density Lipoprotein (HDL) mediates reverse cholesterol transport and it is known to be protective against atherosclerosis. In addition, HDL has potent anti-inflammatory properties that may be critical for protection against other inflammatory diseases. The molecular mechanisms of how HDL can mo...

Descripción completa

Detalles Bibliográficos
Autores principales: De Nardo, Dominic, Labzin, Larisa I., Kono, Hajime, Seki, Reiko, Schmidt, Susanne V., Beyer, Marc, Xu, Dakang, Zimmer, Sebastian, Lahrmann, Catharina, Schildberg, Frank A., Vogelhuber, Johanna, Kraut, Michael, Ulas, Thomas, Kerksiek, Anja, Krebs, Wolfgang, Bode, Niklas, Grebe, Alena, Fitzgerald, Michael L., Hernandez, Nicholas J., Williams, Bryan, Knolle, Percy, Kneilling, Manfred, Röcken, Martin, Lütjohann, Dieter, Wright, Samuel D., Schultze, Joachim L., Latz, Eicke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009731/
https://www.ncbi.nlm.nih.gov/pubmed/24317040
http://dx.doi.org/10.1038/ni.2784
Descripción
Sumario:High Density Lipoprotein (HDL) mediates reverse cholesterol transport and it is known to be protective against atherosclerosis. In addition, HDL has potent anti-inflammatory properties that may be critical for protection against other inflammatory diseases. The molecular mechanisms of how HDL can modulate inflammation, particularly in immune cells such as macrophages, remain poorly understood. Here we identify the transcriptional repressor ATF3, as an HDL-inducible target gene in macrophages that down-regulates the expression of Toll-like receptor (TLR)-induced pro-inflammatory cytokines. The protective effects of HDL against TLR-induced inflammation were fully dependent on ATF3 in vitro and in vivo. Our findings may explain the broad anti-inflammatory and metabolic actions of HDL and provide the basis for predicting the success of novel HDL-based therapies.